|83.92||-0.4200||-0.50%||Vol 7.67M||1Y Perf 8.82%|
|Oct 26th, 2020 16:02 DELAYED|
|- -%||0.08 0.10%|
|Target Price||108.64||Analyst Rating||Moderate Buy 1.64|
|Potential %||29.46||Finscreener Ranking||★★★ 50.28|
|Insiders Trans % 3/6/12 mo.||-/-100/11||Value Ranking||★★★+ 54.67|
|Insiders Value % 3/6/12 mo.||-/-100/-87||Growth Ranking||★★★+ 56.61|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-84||Income Ranking||★★★ 51.33|
|Market Cap||148.10B||Earnings Rating||Buy|
|Price Range Ratio 52W %||55.18||Earnings Date||30th Oct 2020|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||30th Oct 2020|
|Estimated EPS Next Report||2.75|
|EPS Growth Next 5 Years %||5.80|
|Avg. Weekly Volume||7.09M|
|Avg. Monthly Volume||6.93M|
|Avg. Quarterly Volume||7.15M|
AbbVie Inc. (NYSE: ABBV) stock closed at 83.92 per share at the end of the most recent trading day (a -0.5% change compared to the prior day closing price) with a volume of 7.99M shares and market capitalization of 148.10B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 30000 people. AbbVie Inc. CEO is Richard A. Gonzalez.
The one-year performance of AbbVie Inc. stock is 8.82%, while year-to-date (YTD) performance is -5.22%. ABBV stock has a five-year performance of 61.28%. Its 52-week range is between 62.55 and 101.28, which gives ABBV stock a 52-week price range ratio of 55.18%
AbbVie Inc. currently has a PE ratio of 18.00, a price-to-book (PB) ratio of 10.12, a price-to-sale (PS) ratio of 5.36, a price to cashflow ratio of 8.70, a PEG ratio of 2.32, a ROA of 6.71%, a ROC of 13.28% and a ROE of 220.71%. The company’s profit margin is 18.22%, its EBITDA margin is 35.40%, and its revenue ttm is $27.75 Billion , which makes it $15.72 revenue per share.
Of the last four earnings reports from AbbVie Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.75 for the next earnings report. AbbVie Inc.’s next earnings report date is 30th Oct 2020.
The consensus rating of Wall Street analysts for AbbVie Inc. is Moderate Buy (1.64), with a target price of $108.64, which is +29.46% compared to the current price. The earnings rating for AbbVie Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AbbVie Inc. has a dividend yield of 5.60% with a dividend per share of $4.72 and a payout ratio of 77.00%.
AbbVie Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.29, ATR14 : 1.69, CCI20 : -125.19, Chaikin Money Flow : -0.20, MACD : -1.51, Money Flow Index : 40.36, ROC : -4.31, RSI : 38.08, STOCH (14,3) : 21.79, STOCH RSI : 0.59, UO : 41.92, Williams %R : -78.21), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AbbVie Inc. in the last 12-months were: Brian L. Durkin (Buy at a value of $362 705), Carlos Alban (Sold 53 325 shares of value $5 332 554 ), Edward J. Rapp (Buy at a value of $252 617), Jeffrey Ryan Stewart (Sold 23 024 shares of value $2 072 210 ), Timothy J. Richmond (Sold 19 445 shares of value $1 652 825 )
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.